Unlocking the Science of Cannabis
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
Here is a small sampling of Bone Cancer studies by title:
Ready to become a subscriber? Go to our PRICING page.
This type of cancer is relatively rare, with a bimodal age distribution. The first peak is between 10-14 yrs as the most common primary bone cancer of childhood, and then after age 65 as a secondary malignancy.
The cancer cells proliferate within the bones' tissues, eventually forming tumors. Orthodox medicine differentiates between bone cancers originating in the bone, calling these primary and secondary cancers that develop in the bone tissue after spreading from another place (metastasizing) or different primary bone pathology.
There is some correlation between osteosarcoma and specific genetic syndromes, Paget disease, electrical burns, trauma, exposure to beryllium and alkylating agents, FBJ virus, fibrous dysplasia, bone infarction, and infection, ionizing radiation, radium, antiquated contrast agents (e.g., thorotrast), and more.
Tumors may develop slowly over time, sometimes weeks to months, before making their presence known through gradually increasing discomfort, visible deformities, systemic symptoms (rarely), and pain. In addition, the tumor often exerts pressure from the inside, which, combined with a loss of bone density and strength, may produce fractures of the bones or make them much more vulnerable to breakage.
Orthodox medical treatments are limited to chemotherapy, radiation, and surgeries (amputations). However, these modern medical techniques can now extend these patients' life expectancy, and the five-year overall survival rate is about 68%.
If you are interested in the interaction potential of specific pharmaceuticals with THC, consider visiting CANN-DIR, published by Penn State College of Medicine.
If you are interested in the interaction potential of specific pharmaceuticals with CBD, consider visiting CANN-DIR, published by Penn State College of Medicine.
In general, when using cannabinoid-based therapeutics that contain both THC and CBD consider the ratio between them and weigh the relevant information displayed in the individual THC and CBD Drug Interaction windows accordingly.
If you are interested in the interaction potential of specific pharmaceuticals with both primary cannabinoids and THC/CBD, consider visiting CANN-DIR, published by Penn State College of Medicine.
Concerns about Cannabis and Cancer-related Immunotherapies:
Some recent clinical observational studies have suggested that the co-administration of cannabinoid-based therapeutics and immunotherapy or immune checkpoint inhibitors in the treatment of certain types of cancer has been associated with worse overall survival rates (T. Taha et al., 2019; A. Biedny et al., 2020; G. Bar-Sela et al., 2020).
However, other studies have suggested that the co-commitment use of immune checkpoint inhibitors and cannabis-induced no such deleterious effects. More specifically, one trial was conducted on animals resulting in data suggesting that cannabis did not negatively affect the properties of immune checkpoint inhibitors (B. Waissengrin et al., 2023). The same authors compared the previous study results with findings from a cohort of 201 patients with metastatic non-small cell lung cancer who received treatment with monotherapy pembrolizumab as a first-line treatment and adjunct cannabis to treat mainly pain and loss of appetite. Their time to tumor progression was 6.1 versus 5.6 months, and overall survival differed between 54.9 versus 23.6 months in cannabis-naïve patients and cannabis-using patients, respectively. However, while numerically different, the authors write that these differences were not statistically significant, leading them to suggest that “These data provide reassurance regarding the absence of a deleterious effect of cannabis in this clinical setting.”
Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.